Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits
Jan 20 (Reuters) – Japan’s Shionogi & Co said on Tuesday it ​would pay $2.13 billion for new…
Should You Buy Pfizer While It’s Under $30?
Pfizer has been struggling for several years. The company’s pipeline could help it turn things around. It also…
Where Will Pfizer Be in 5 Years?
Pfizer’s stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Pfizer, YaoPharma sign $150M GLP-1 obesity drug collaboration
Key Terms phase 1 medical Phase 1 is the first stage of testing…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…
2 Giant Healthcare Stocks to Buy Hand Over Fist in November
Medical device maker Medtronic boasts an attractive yield and a long history of dividend growth. Pfizer is demonstrating…
How Recent Moves Are Rewriting the Story for Pfizer
Pfizer’s fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate…
Who’s Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Eli Lilly’s GLP-1 drug is now the world’s best-selling drug. Novo Nordisk is struggling with declining market share.…
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an…